Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.

Abdel-Hady A, El-Hindawi A, Hammam O, Khalil H, Diab S, El-Aziz SA, Badawy M, Ismail A, Helmy N, Kamel N, Anis S, Kholy AE, Osili KA, Abdel-Hady A, Nour H, Akl M.

Open Access Maced J Med Sci. 2017 Mar 20;5(2):147-154. doi: 10.3889/oamjms.2017.037. eCollection 2017 Apr 15.

2.

Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.

Tsourlakis MC, Stender A, Quaas A, Kluth M, Wittmer C, Haese A, Graefen M, Steurer S, Simon R, Korbel J, Weischenfeldt J, Huland H, Sauter G, Schlomm T, Minner S.

BMC Cancer. 2016 Aug 17;16:641. doi: 10.1186/s12885-016-2674-6.

3.

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.

Noh BJ, Sung JY, Kim YW, Chang SG, Park YK.

Oncol Lett. 2016 Jun;11(6):3621-3630. Epub 2016 Apr 19.

4.

TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Yılmaz Ö, Berber U, Okçelik S, Soydan H, Ateş F, Karademir K.

Turk J Urol. 2016 Jun;42(2):60-3. doi: 10.5152/tud.2016.94763.

5.

DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.

Liu W.

Asian J Androl. 2016 Jul-Aug;18(4):533-42. doi: 10.4103/1008-682X.177120. Review.

6.

Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients.

Yoon N, Lim S, Kang SY, Kwon GY, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY.

Asian J Androl. 2017 May-Jun;19(3):346-349. doi: 10.4103/1008-682X.172826.

7.

Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2015 Dec 1;16:1021. doi: 10.1186/s12864-015-2235-4. Erratum in: BMC Genomics. 2016;17:424.

8.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

9.

RNA biomarkers to facilitate the identification of aggressive prostate cancer.

Pellegrini KL, Sanda MG, Moreno CS.

Mol Aspects Med. 2015 Nov;45:37-46. doi: 10.1016/j.mam.2015.05.003. Epub 2015 May 27. Review.

10.

Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.

Park HK, Kim H, Kim HG, Cho YM, Jung WY, Han HS, Hwang TS, Kwon GY, Lim SD.

J Korean Med Sci. 2015 May;30(5):533-41. doi: 10.3346/jkms.2015.30.5.533. Epub 2015 Apr 15.

11.

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Kelly GM, Kong YH, Dobi A, Srivastava S, Sesterhenn IA, Pathmanathan R, Tan HM, Tan SH, Cheong SC.

Mol Clin Oncol. 2015 Jan;3(1):23-30. Epub 2014 Sep 18.

12.

Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?

Ren G, Zhang Y, Mao X, Liu X, Mercer E, Marzec J, Ding D, Jiao Y, Qiu Q, Sun Y, Zhang B, Yeste-Velasco M, Chelala C, Berney D, Lu YJ.

OMICS. 2014 Oct;18(10):615-24. doi: 10.1089/omi.2014.0042. Epub 2014 Sep 4.

13.

The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.

Eguchi FC, Faria EF, Scapulatempo Neto C, Longatto-Filho A, Zanardo-Oliveira C, Taboga SR, Campos SG.

Sci Rep. 2014 Jul 10;4:5640. doi: 10.1038/srep05640.

14.

ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.

Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y, Yuan H, Ren Y, Zhang J, Qin X, Han B.

PLoS One. 2014 Feb 7;9(2):e84959. doi: 10.1371/journal.pone.0084959. eCollection 2014.

15.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.

Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

J Cancer. 2013 Jul 5;4(6):468-72. doi: 10.7150/jca.6568. Print 2013.

16.
17.

Prostate cancer research in China.

Ren SC, Chen R, Sun YH.

Asian J Androl. 2013 May;15(3):350-3. doi: 10.1038/aja.2013.37. Epub 2013 Apr 22. Review.

18.

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.

Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A, Steiner E, Horninger W, Bektic J, Ladurner-Rennau M, Rubin MA, Demichelis F, Klocker H.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):132-8. doi: 10.1038/pcan.2013.4. Epub 2013 Feb 5.

19.

Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Xue L, Mao X, Ren G, Stankiewicz E, Kudahetti SC, Lin D, Beltran L, Berney DM, Lu YJ.

Am J Cancer Res. 2012;2(6):736-44. Epub 2012 Nov 20.

20.

ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.

Suh JH, Park JW, Lee C, Moon KC.

Korean J Pathol. 2012 Oct;46(5):423-8. doi: 10.4132/KoreanJPathol.2012.46.5.423. Epub 2012 Oct 25.

Supplemental Content

Support Center